Ensayos Clínicos de Tiroides
Abiertos a Reclutamiento en España
Actualizado septiembre 2021
Información Pública obtenida a partir de: Clinical Trials.gov; EU Clinical Trials Register; REEC (AEMPS)
Para iniciar la búsqueda, teclee el texto en la barra a continuación.
| EudraCT-Number | NCT | CÓDIGO-ESTUDIO | TÍTULO ESTUDIO | FASE | INDICACIÓN | ESTADO | MEDICACIÓN | CENTRO | PROMOTOR | |
|---|---|---|---|---|---|---|---|---|---|---|
| N.A | 4970134 | TTCC-2020-02 | Spanish Observational Study for MOLecular Characterization of THYroid Carcinoma MOLTHY Project | Observacional | This project is a retrospective observational study based on the molecular characterization of a Spanish population of patients with refractory radio-iodine differentiated thyroid cancer (DTC) and medullary thyroid carcinoma (MTC) with advanced and / or metastatic disease undergoing systemic treatment, or under clinical observation. | RECLUTANDO | N.A | H.U. Clínic (Barcelona) H.U. Miguel Servet (Zaragoza) H.U. La Paz (Madrid) H.U. La Fe (Valencia) H.U. Vall d´Hebron (Barcelona) H.U. Ramón y Cajal (Madrid) H.U. Marqués de Valdecilla (Santander) ICO Hospitalet H. General de Valencia Fundación Althaia (Manresa) H.U. Parc Taulí (Sabadell) ICO Girona | TTCC | |
| 2018-002612-27 | 3780517 | BOS172738-01 | A Phase 1 Study of BOS172738 in Patients With Advanced Solid Tumors With RET Gene Alterations Including Non-Small Cell Lung Cancer (NSCLC) and Medullary Thyroid Cancer(MTC) | Phase I | This study will be conducted to assess the safety and tolerability of BOS172738 when administered to patients with advanced solid tumors with rearranged during transfection (RET) gene alterations and also to establish the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) of BOS172738. | RECLUTANDO | BOS172738 | H.U. Virgen de la Victoria (Málaga) ICO Badalona H.U. Dexeus (Barcelona) Start_Sanchinarro (Madrid) Start_F.J.Díaz (Madrid) | Boston Pharmaceuticals | |
| 2018-004334-15 | 4234113 | SC103 | A Multicenter Open-label Phase 1/1b Study to Evaluate the Safety and Preliminary Efficacy of SO-C101 as Monotherapy and in Combination With Pembrolizumab in Patients With Selected Advanced/Metastatic Solid Tumors | Phase I | HNSCC & Thyroid, A multicenter open-label phase 1/1b study to evaluate the safety and preliminary efficacy of SO-C101 as monotherapy and in combination with pembrolizumab in patients with selectedadvanced/metastatic solid tumors | RECLUTANDO | SO-C101 Pembrolizuma | H.U. Vall d´Hebron (Barcelona) | SOTIO | |
| 2017-001792-24 | 3170960 | XL184-021 | A Phase 1b Dose-Escalation Study of Cabozantinib (XL184) Administered Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors | Phase Ib | Expansion Cohort 18: DTC subjects (follicular, papillary, and poorly differentiated histologies) who are radioactive iodine (RAI) refractory or deemed ineligible for treatment with RAI. | RECLUTANDO | Atezolizumab Cabozantinib | No especificado por promotor | Exelixis | |
| 2016-004390-41 | 3037385 | BLU-667-1101 (ARROW) | A Phase 1 Study of the Highly-selective RET Inhibitor, BLU-667, in Patients With Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors (ARROW) | Phase I/II | This is a Phase 1/2, open-label, first-in-human (FIH) study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antineoplastic activity of pralsetinib (BLU-667) administered orally in patients with medullary thyroid cancer, | RECLUTANDO | Pralsetinib (BLU-667) | H.U. Vall d´Hebron (Barcelona) H.U. Clínic (Barcelona) ICO Hospitalet H.U. Ramón y Cajal (Madrid) H.U. 12 de Octubre (Madrid) | Blueprint Medicines Corporation | |
| 2017-000800-59 | 3157128 | LOXO-RET-17001 | A Phase 1/2 Study of Oral LOXO-292 in Patients With Advanced Solid Tumors, Including RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors With RET Activation (LIBRETTO-001) | Phase I/II | This is a Phase 1/2, open-label, first-in-human study designed to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor activity of selpercatinib (also known as LOXO-292) administered orally to patients with advanced solid tumors, including RET-fusion-positive solid tumors, medullary thyroid cancer (MTC) and other tumors with RET activation. | RECLUTANDO | LOXO-292 | H.U. Vall d´Hebron (Barcelona) Start_F.J.Díaz (Madrid) Start_Sanchinarro (Madrid) | Loxo Oncology, Inc | |
| 2015-002067-41 | 2628067 | 3475-158 | A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects With Advanced Solid Tumors (KEYNOTE 158) | Phase II | Thyroid Carcinoma Salivary Gland Carcinoma (sarcomas and mesenchymal tumors are excluded) | RECLUTANDO | Pembrolizumab | H.U. Vall d´Hebron (Barcelona) H.U. Ramón y Cajal (Madrid) H.U. 12 de Octubre (Madrid) | Merck Sharp & Dohme Corp | |
| 2018-001066-42 | 3753919 | GETNE-T1812 | Estudio de fase II de durvalumab (MEDI4736) más tremelimumab para el tratamiento de pacientes con carcinoma tiroideo avanzado, resistente al tratamiento y progresivo (ensayo DUTHY) | Phase II | Carcinoma de tiroides diferenciado, avanzado, refractario al yodo radiactivo, incluyendo carcinoma tiroideo papilar, folicular, de células de Hürthle y poco diferenciado (CDT). Carcinoma medular de tiroides (CMT) avanzado. Cáncer anaplásico de tiroides (CAT) avanzado. | RECLUTANDO | Durvalumab Tremelimumab | CUN H.U. Vall d´Hebron (Barcelona) ICO Hospitalet H.U. Morales Meseguer (Murcia) H.U. Ramón y Cajal (Madrid) H.U. 12 de Octubre (Madrid) H.U. La Paz (Madrid) H.U. Virgen de la Victoria (Málaga) H.U. Clínic (Barcelona) M.D. Anderson (Madrid) H.U. Sanchinarro (Madrid) H.U. Clínico San Carlos (Madrid) C.H. Castellón IVO Valencia H.U. Alvaro Cunqueiro (Vigo) | Spanish Group of Neuroendocrine Tumors (GETNE) | |
| 2016-003616-13 | 3093116 | TPX-0005-01 | A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1) | Phase II( in Spain) | A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1) | RECLUTANDO | Repotrectinib (TPX-0005) | CUN H.U. Dexeus (Barcelona) H.U. Vall d´Hebron (Barcelona) M.D. Anderson (Madrid) Start_F.J.Díaz (Madrid) Start_Sanchinarro (Madrid) H.U. 12 de Octubre (Madrid) IVO Valencia | Turning Point Therapeutics, Inc. | |
| 2019-002279-32 | 4400474 | GETNE-T1914 | Exploratory Basket Trial of Cabozantinib Plus Atezolizumab in Advanced and Progressive Neoplasms of the Endocrine System. CABATEN Study | Phase II | CABATEN is a multicohort phase II study of cabozantinib plus atezolizumab in advanced and progressive tumors from endocrine system. | RECLUTANDO |
| No especificado por promotor | Grupo Español de Tumores Neuroendocrinos | |
| 2019-001978-28 | 4211337 | J2G-MC-JZJB | A Multicenter, Randomized, Open-label, Phase 3 Trial Comparing Selpercatinib to Physicians Choice of Cabozantinib or Vandetanib in Patients With Progressive, Advanced, Kinase Inhibitor Naïve, RET-Mutant Medullary Thyroid Cancer (LIBRETTO-531) | Phase III | The reason for this study is to see if the study drug selpercatinib is safe and more effective compared to a standard treatment in participants with rearranged during transfection (RET)-mutant medullary thyroid cancer (MTC) that cannot be removed by surgery or has spread to other parts of the body. | RECLUTANDO | Selpercatinib Cabozantinib Vandetanib | H.U. Virgen de la Victoria (Málaga) H.U. Clínico San Carlos (Madrid) H.U. 12 de Octubre (Madrid) H.U. La Paz (Madrid) H.U. Ramón y Cajal (Madrid) H.U. Gregorio Marañón (Madrid) ICO Girona ICO Hospitalet H.U. Vall d´Hebron (Barcelona) C.U.N. H.U. Miguel Servet (Zaragoza) | Loxo Oncology, Inc | |
| N.A | 3765333 | REGETNE-Tiroides | Descriptive Observational Epidemiological Study on the Characteristics of Thyroid Cancer in Patients Treated in Oncology Services of Spanish Centers: National Registry of Thyroid Cancer - Differentiated, Medullary and Anaplastic | Descriptive Observational | NA | RECLUTANDO | NA | H.U. Vall d´Hebron (Barcelona) | GETNE |
Puede seleccionar el número de filas a representar entre: 4, 8 o 10